Received Jun 10, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HEPAB | HEP A + HEP B (TWINRIX) | GLAXOSMITHKLINE BIOLOGICALS | 2 | — | — |
administration of a late second dose of Twinrix; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 70-year-old male patient who received HAB (Twinrix) suspension for injection in pre-filled syringe for prophylaxis. Previously administered products included Twinrix (received first dose on 15-DEC-2025). On 07-MAY-2026, the patient received the 2nd dose of Twinrix. On 07-MAY-2026, an unknown time after receiving Twinrix, the patient experienced drug dose administration interval too long (Verbatim: administration of a late second dose of Twinrix). The outcome of the drug dose administration interval too long was not applicable. This report is made by GSK without prejudice and does not imply any admission or liability for the incident or its consequences. Additional Information: GSK Receipt Date: 05-JUN-2026 The pharmacist had inquired about when the third dose should be administered. The batch number was not provided upon follow up with the reporter.